Table 1.

Author	Study design	Number of patients (n)	Duration	Agent	Response	Bleeding events
Janczak [19] (2018)	Prospective, non-cirrhotic, Atypical sites	Total N=36 PVT N= 16		Rivaroxaban Apixaban	Recurrence rate 7.3 % (n=2) (both had malignancy)	Minor N=1 (3.6%) Major N=2 (7.2%)
Qi [20] (2017)	Case report, cirrhotic, CPT not specified	SMV, splenic vein, N=1	11 weeks	Rivaroxaban	Recanalization	Melena and hematemesis
Nery [21] (2017)	Case report Non-cirrhotic	N=1	>6m	Rivaroxaban 20 mg daily	Complete recanalization L branch, partial recanalization right branch	None
De Gottardi [10] (2016)	Retrospective, Both cirrhotic and non-cirrhotic, Splanchnic	Total, N= 94 PVT N= 80 (Non cirrh- N=38 Cirrh- N=22)	Non-cirrhotic 13.1 m cirrhotic 9.6 m	Rivaroxaban Apixaban Dabigatran	Not studied	Cirrhosis: Minor, n=7, Major, n=2 Non-cirrh: Minor, n= 4 Major, n=1
Hum [9] (2016)	Retrospective, Cirrhotic, CPT A, B & C All indications	Total, N= 27 PVT N=4		Rivaroxaban 15 mg bid +/- 20 mg daily load, Apixaban 5mg bid +/- 10mg bid load, No bridging	Recurrence rate 4% (n=1)	Major N=1 (4%) Minor, N=7
Yang [12] (2016)	Case report, cirrhotic CPT A	N=1	6 m	Rivaroxaban 15 mg bid x 3 wks, then 20 mg/d	Complete recanalization	None
Intagliata [8] (2015)	Retrospective, cirrhotic, CPT A and B	Total N= 20 PVT, N=12	10.6 m	Apixaban Rivaroxaban	Not studied	Major, n=1
Martinez [22] (2014)	Case report, Cirrhotics, CPT A	N=1	6 m	Rivaroxaban 20 mg /d	Complete recanalization	None
Lenz [11] (2014)	Case report, Cirrhotic CPT A	N=1	5 m	Rivaroxaban 10 mg daily	Complete recanalization	None
Pannach [23] (2013)	Case report, Non-cirrhotic	N=1	>4 weeks	Rivaroxaban 20 mg daily	Complete recanalization	None

CPT: Child Pugh Turcotte; Cirrh: cirrhosis.